SEC Form 4 · accession 0001127602-18-004003
Elevance Health, Inc. · ELV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Swedish
Officer — Executive Chairman · Director
Period of report
Feb 1, 2018
Accepted (ET)
Feb 5, 2018 · 4:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001156039
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 1, 2018 | M | 17,803 | $67.44 | A | 84,346 | D | |
| Common Stock | Feb 1, 2018 | M | 46,600 | $89.44 | A | 130,946 | D | |
| Common StockF2 | Feb 1, 2018 | S | 6,800 | $242.40 | D | 124,146 | D | |
| Common StockF3 | Feb 1, 2018 | S | 19,100 | $243.82 | D | 105,046 | D | |
| Common StockF4 | Feb 1, 2018 | S | 26,703 | $244.52 | D | 78,343 | D | |
| Common StockF5 | Feb 1, 2018 | S | 8,900 | $245.71 | D | 69,443 | D | |
| Common StockF6 | Feb 1, 2018 | S | 1,900 | $246.69 | D | 67,543 | D | |
| Common StockF7 | Feb 1, 2018 | S | 1,000 | $247.73 | D | 66,543 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F8 | $67.44 | Feb 1, 2018 | M | 17,803 | D | — | Apr 1, 2020 | Common Stock | 17,803 | 0 | D |
| Employee Stock Option (Right to Buy)F9 | $89.44 | Feb 1, 2018 | M | 46,600 | D | — | Mar 3, 2021 | Common Stock | 46,600 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 2, 2017, as modified on December 11, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $241.96 to $242.95. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $243.18 to $244.17. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $244.18 to $245.17. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $245.24 to $246.20. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $246.36 to $246.89. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $247.62 to $247.95. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8The option represents a right to purchase a total of 102,303 shares, and is exercisable in six semi-annual installments, with three installments of 17,050 shares and three installments of 17,051 shares each, beginning on October 1, 2013, which is the six-month anniversary of the option grant date.
- F9The option represents a right to purchase a total of 114,100 shares, and is exercisable in six semi-annual installments, with two installments of 19,016 shares and four installments of 19,017 shares each, beginning on September 3, 2014, which is the six-month anniversary of the option grant date.